The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats

Bone

Volumn 34, Issue 3, 2004, Pages 384-392

  Goss, P E ^a   Qi, S ^a   Josse, R G ^b   Pritzker, K P H ^c,d   Mendes, M ^d   Hu, H ^a   Waldman, S D ^d   Grynpas, M D ^c,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Biomechanics; Bone mineral density; Breast cancer; Exemestane; Postmenopausal osteoporosis

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; CHOLESTEROL; EXEMESTANE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OSTEOCALCIN; PYRIDINOLINE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE STRENGTH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; FEMALE; FEMUR; LIPID METABOLISM; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OVARIECTOMY; RAT; RAT STRAIN; TRIACYLGLYCEROL BLOOD LEVEL; VERTEBRA;

ANDROSTADIENES; ANIMALS; AROMATASE; AROMATASE INHIBITORS; BONE RESORPTION; ENZYME INHIBITORS; FEMALE; FEMUR; LUMBAR VERTEBRAE; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 1542346356     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.11.006     Document Type: Article

References (52)

1. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
2. Assikis V.J., Buzdar A. Recent advances in aromatase inhibitor therapy for breast cancer. Semin. Oncol. 29(Suppl. 11):2002;120-128.
3. Chung C.T., Carlson R.W. The role of aromatase inhibitors in early breast cancer. Curr. Treatm. Opt. Oncol. 4:2003;133-140.
4. Thurlimann B., Paridaens R., Seri D., Bonneterre J., Roche H., Murray R.et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur. J. Cancer. 33:1997;1767-1773.
5. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G.et al. The ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 359:2002;2131-2139.
6. Eastell R., Adams J. Results of the 'Arimidex' (anastrozole, A), tamoxifen (T), alone or in combination (C) (ATAC) trial: effects on bone mineral density (BMD) and bone turnover (ATAC Trialists' Group). Ann. Oncol. 13(Suppl. 5):2002;32.
7. Salamone L.M., Gregg E., Wolf R.L., Epstein R.S., Black D., Palermo L.et al. Are menopausal symptoms associated with bone mineral density and changes in bone mineral density in premenopausal women? Maturitas. 29:1998;179-187.
8. Gordon T., Kannel W.B., Hjortland M.C., McNamara P.M. Menopause and coronary heart disease: the Framingham study. Ann. Intern. Med. 89:1978;157-161.
9. Matthews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Cagguila A.W., Wing R.R. Menopause and risk factors for coronary heart disease. N. Engl. J. Med. 321:1989;641-646.
10. Giudici D., Ornati G., Briatico G., Buzzetti F., Lombardi P., di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J. Steroid Biochem. 30:1988;391-394.
11. Yamazaki I., Yamaguchi H. Characteristics of an ovariectomized osteopenic rat model. J. Bone Miner. Res. 4:1989;13-22.
12. Kalu D.N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15:1991;175-192.
13. Wronski T.J., Yen C.-F. The ovariectomized rat as an animal model for postmenopausal bone loss. Cell Mater. (Suppl. 1):1991;69-74.
14. Martel C., Picard S., Richard V., Belanger A., Labrie C., Labrie F. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem. Mol. Biol. 74:2000;45-56.
15. Lundeen S.G., Carver J.M., Mckean M.L., Winneker R.C. Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology. 138:1997;1552-1558.
16. Nagy T.R., Clair A.L. Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes. Res. 8:2000;392-398.
17. Kasra M., Vanin C.M., MacLusky N.J., Casper R.F., Grynpas M.D. Effect of different estrogen and progestin regimens on the mechanical properties of rat femur. J. Orthop. Res. 15:1997;118-123.
18. Chachra D., Kasra M., Vanin C.M., MacLusky N.J., Casper R.F., Grynpas M.D. The effect of different hormone replacement therapy regimens on the mechanical properties of rat vertebrae. Calcif. Tissue Int. 56:1995;130-134.
19. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J.et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J. Bone Miner. Res. 2:1987;595-610.
20. Quarles D.L., Lobaugh B. Equivalency of various methods for estimating osteoid seam width. J. Bone Miner. Res. 4:1989;671-677.
21. Huffer W.E., Lepoff R.B. An indirect method of measuring widths suitable for automated bone histomorphometry. J. Bone Miner. Res. 7:1992;1417-1427.
22. Huffer W.E., Ruegg P., Zhu J.-M., Lepoff R.B. Semiautomated methods for cancellous bone histomorphometry using a general-purpose video image analysis system. J. Microsc. 173:1994;53-66.
23. Steiniche T. Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities. APMIS Suppl. 51:1995;1-44.
24. Goss P.E., Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol. 19:2001;881-894.
25. Goss P.E., Strasser K. Chemoprevention with aromatase inhibitors - Trial strategies. J. Steroid Biochem. Mol. Biol. 79:2001;143-149.
26. Harper-Wynne C., Ross G., Sacks N., Dowsett M. A pilot prevention study of the aromatase inhibitor letrozole: effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women. Breast Cancer Res. Treat. 69:2001;225.
27. Harper-Wynne C., Ross G., Sacks N., Salter J., Nasiri N., Iqbal J.et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol. Biomarkers Prev. 11:2002;614-621.
28. Zilembo N., Bajetta E., Martinetti A., Polli A., Pozzi P., Ferrari L.et al. Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA). Eur. J. Cancer. 37(Suppl. 6):2001;S193.
29. Goss P.E., Thomsen T., Banke-Bochita J., Lowery C., Asnis A. A randomized, placebo-controlled, explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12-week treatment with exemestane or letrozole. Breast Cancer Res. Treat. 76(Suppl. 1):2002;S76.
30. Yoshitake K., Yokota K., Kasugai Y., Kagawa M., Sukamoto T., Nakamura T. Effects of 16 week of treatment with tibolone on bone mass and bone mechanical and histomorphometric indices in mature ovariectomized rats with established osteopenia on a low-calcium diet. Bone. 25:1999;311-319.
31. Lane N.E., Kumer J.L., Majumdar S., Khan M., Lotz J., Stevens R.E.et al. The effects of synthetic conjugated estrogens, a (cenestin) on trabecular bone structure and strength in the ovariectomized rat model. Osteoporos. Int. 13:2002;816-823.
32. Li X.X., Hara I., Matsumiya T. Effects of osthole on postmenopausal osteoporosis using ovariectomized rats; comparison to the effects of estradiol. Biol. Pharm. Bull. 25:2002;738-742.
33. Hornby S.B., Evans G.P., Hornby S.L., Pataki A., Glatt M., Green J.R. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif. Tissue Int. 72:2003;519-527.
34. Dempster D.W., Birchman R., Xu R., Lindsay R., Shen V. Temporal changes in cancellous bone structure of rats immediately after ovariectomy. Bone. 16:1995;157-161.
35. Ohnishi H., Nakamura T., Narusawa K., Murakami H., Abe M., Barbier A.et al. Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats. Bone. 21:1997;335-343.
36. Ammann P., Bourrin S., Bonjour J.P., Brunner F., Meyer J.M., Rizzoli R. The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats. Osteoporos. Int. 10:1999;369-376.
37. Lee L.L., Lee J.S.C., Waldman S.D., Casper R.F., Grynpas M.D. Polycyclic aromatic hydrocarbons present in cigarette smoke cause bone loss in an ovariectomized rat model. Bone. 30:2002;917-923.
38. Lea C.K., Flanagan A.M. Physiological plasma levels of androgens reduce bone loss in the ovariectomized rat. Am. J. Physiol. 274:1998;E328-E335.
39. Martel C., Sourla A., Pelletier G., Labrie C., Fournier M., Picard S.et al. Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol. 157:1998;433-442.
40. Lea C.K., Flanagan A.M. Ovarian androgens protect against bone loss in rats made oestrogen deficient by treatment with ICI 182,780. J. Endocrinol. 160:1999;111-117.
41. Notelovitz M. Androgen effects on bone and muscle. Fertil. Steril. 77(Suppl. 4):2002;34-41.
42. Chesnut C.H., Ivey J.L., Gruber H.E., Matthews M., Nelp W.B., Sisom K.et al. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action. Metabolism. 32:1983;571-580.
43. Buchanan J.R., Hospodar P., Myers C., Leuenberger P., Demers L.M. Effect of excess endogenous androgens on bone density in young women. J. Clin. Endocrinol. Metab. 67:1988;937-943.
44. Slemenda C., Longcope C., Peacock M., Hui S., Johnston C.C. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J. Clin. Invest. 97:1996;14-21.
45. Johannessen D.C., Engan T., di Salle E., Zurlo M.G., Paolini J., Ornati G.et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin. Cancer Res. 3:1997;1101-1108.
46. Brown M.S., Goldstein J.L. The estradiol stimulated lipoprotein receptor of rat liver. J. Biol. Chem. 254:1980;10454-10471.
47. Chao Y.S., Windler E.E., Chen G.C., Havel R.J. Hepatic catabolism of rat and human lipoproteins in rats treated with 17 α-ethynyl estradiol. J. Biol. Chem. 254:1979;11360-11366.
48. Elisaf M.S., Bairaktari E.T., Nicolaides C., Kakaidi B., Tzallas C.S., Katsaraki A.et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur. J. Cancer. 37:2001;1510-1513.
49. Lohrisch C., Paridaens R., Dirix L.Y., Beex L., Nooij M., Cameron D.et al. No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin® (exemestane [E]) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European organization of research and treatment of cancer (Breast group) trial with Pharmacias' Upjohn. Proc.-Am. Soc. Clin. Oncol. 20:2001;43a.
50. Weidemann W., Hanke H. Cardiovascular effects of androgens. Cardiovasc. Drug Rev. 20:2002;175-198.
51. Bernini G.P., Moretti A., Sgro M., Argenio G.F., Barlascini C.O., Cristofani R.et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause. 8:2001;43-50.
52. Eckardstein A., Wu F.C. Testosterone and atherosclerosis. Growth Horm. IGF Res. 13(Suppl. A):2003;S72-S84.